Tag Archives: CV Therapeutics

Gilead Buys CV Therapeutics (Update 1)

The morning’s other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that it will purchase CV Therapeutics for $1.4 billion. The sudden move frees Palo Alto-based cardiovascular company CV Therapeutics from the hostile embrace of Astellas Pharma, ending a messy $1.1 billion takeover attempt. With the acquisition, Gilead, […]
Posted in Deals | Also tagged , , , , , , | 3 Comments

Astellas Keeps After CV Therapeutics

Astellas bid for CV Therapeutics turned hostile this morning when the Japanese drug firm offered $1 billion dollars for the company directly to shareholders. The CVT board rejected Astellas’s second proposal last Friday stating that the Astellas proposal undervalued the company and is not in the best interest of the shareholders. In a press release […]
Posted in Deals | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta